Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-07, Vol.16 (13), p.2478
Main Authors: Garg, Pankaj, Malhotra, Jyoti, Kulkarni, Prakash, Horne, David, Salgia, Ravi, Singhal, Sharad S
Format: Article
Language:English
Subjects:
Artificial intelligence
Breast cancer
Cancer therapies
Cell therapy
Chemotherapy
Clinical outcomes
Cytotoxic agents
Cytotoxicity
Drug resistance
Epigenetics
Genes
Glycoproteins
Hypoxia
Immune checkpoint inhibitors
Immunotherapy
Kinases
Lymphocytes T
Medical innovations
Metabolism
Mutation
Nanotechnology
Patients
Precision medicine
Proteins
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into drug resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, the promising avenues offered by targeted therapies, combination treatments, immunotherapies, and precision medicine approaches are highlighted. Specifically, the synergistic effects of combining traditional cytotoxic agents with molecularly targeted inhibitors to circumvent resistance pathways are examined. Additionally, the evolving landscape of immunotherapeutic interventions, including immune checkpoint inhibitors and adoptive cell therapies, is explored in terms of bolstering anti-tumor immune responses and overcoming immune evasion mechanisms. Moreover, the significance of biomarker-driven strategies for predicting and monitoring treatment responses is underscored, thereby optimizing therapeutic outcomes. For insights into the future direction of cancer treatment paradigms, the current review focused on prevailing drug resistance challenges and improving patient outcomes, through an integrative analysis of these emerging therapeutic strategies.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16132478